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ABSTRACT 
Objectives: The objective of this work is to synthesize novel imidazole and fused imidazole derivatives using 5-arylidene-2-hydrazino-3-phenyl 
imidazolin-4-ones (5a-c) as key intermediate. The structure of the newly synthesized compounds was characterized using IR, 1HNMR, Mass 
spectroscopy, elemental analysis and some representative 13
Methods: The target compounds were synthesized starting from 5-arylidene-2-hydrazino-3-phenyl imidazolin-4-ones (5a-c) which prepared from 
the appropriate 5-arylidene-2-(methylthio)-3-phenyl imidazolin-4-ones (3a-c). Several synthetic pathways were be used for the preparation of the 
targets. Some of the newly synthesized compounds were evaluated for their cytotoxic activity against breast carcinoma and colon carcinoma cell 
lines. On the other hand, the antimicrobial activity evaluation of some newly prepared compounds was performed using cup plate diffusion method. 
CNMR. 
Results: Compound 5c was the most active one against breast carcinoma (IC50=3.3 ug/ml) and colon carcinoma cell lines (IC50
Conclusion: The present work led to the development of promising antitumor compounds containing substituted imidazolidin-5-one or imidazotriazol-
6-one skeletons. Compounds 5c showed the highest potency at low µg/ml level against breast MCF-7 and colon HCT116 cell lines. On the other hand, 
most of the newly synthesized compounds showed broad spectrum antimicrobial activity when cup plate diffusion method was performed. 
=4.73 ug/ml) when 
compared with doxorubicin as standard. Molecular docking studies further supported the highest potency of 5c and further help understanding the 
various interactions between the ligand and enzyme active sites. On the other hand, the antimicrobial activity evaluation showed that most of the 
evaluated compounds exhibited broad spectrum activity. 
Keywords: Imidazole, Fused imidazole derivatives, Cytotoxic, Antimicrobial activity. 
 
INTRODUCTION 
Imidazole and its derivatives have gained remarkable importance 
due to their widespread biological activities and their use in 
synthetic chemistry. This ring system is present in several important 
biological building blocks, such as purine, histamine, histidine and 
nucleic acid. Various biologically active synthetic compounds have 
imidazole moiety in their structure, include analgesic, anti-
inflammatory, antiparasitic, platelet aggregation inhibitors, and 
antiepileptic agents [1-5]. Imidazole can be found in many other 
drugs such as dacarbazine [6], metronidazole [7], cimetidine [8], 
phenytoin [9], thyroliberin [10], methimazole [11], pilocarpine [12], 
and etomidate [13] which are used as antineoplastic, antibiotic, 
antiulcerative, benzodiazepine antagonist, prohormone, 
antiperthyroid, muscarinic receptor antagonist and hypnotic agents, 
respectively. The previous important therapeutic properties of 
imidazole related drugs have encouraged the medicinal chemists to 
synthesize and evaluate a large number of novel molecules. 
Accordingly, in this investigation, it was of interest to synthesize 
some novel imidazole and fused imidazole derivatives starting from 
3-phenyl-2-thioxoimidazolidin-4-one (1) and evaluates their 
cytotoxic as well as their antimicrobial activities. 
MATERIALS AND METHODS 
Melting points were determined on a Griffin apparatus and are 
uncorrected. IR spectra were determined as KBr discs on Schimadzu 
FTIR 8000 spectrophotometer (Japan).1HNMR, 13CNMR spectra were 
carried out on Varian Gemini 300 MHz and 75 MHz 
spectrophotometer (Switzerland) using TMS as internal standard 
and DMSO-d6
Synthesis of 3-phenyl-5-(thiophen-2-ylmethylene)-2-thioxo-
imidazolidin-4-one (2a)  
 as solvent. Mass spectra were run on Hewlett Packard 
5988 spectrometer Microanalytical Center, Cairo University, Egypt. 
Elemental analysis was carried out at the Regional Center for 
Mycology and Biotechnology, Al-Azhar University Campus, Nasr City, 
Cairo, Egypt. Progress of the reaction was monitored by TLC using 
TLC sheets pre coated with UV fluorescent silica gel Merk 60 F254 
and spots were visualized by iodine vapour or irradiation with UV 
lamp. Compounds 1, 2b, 2c and 3b were be synthesized according to 
the reported methods [14-17]. 
To a mixture of compound 1 (1.15 g, 6 mmol) and piperidine (3 
drops) in absolute ethanol (30 ml), thiophen-2-aldehyde (0.67 g, 
6.04 mmol) was added. The reaction mixture was stirred for 12 h at 
room temperature until the starting material was consumed [TLC, 
Ethyl acetate: Petroleum ether (60:80оC), (3:2)]. The reaction 
mixture was diluted with cold water (20 ml) and neutralized with 
dil. HCl (1 ml). The separated yellow solid was filtered and 
crystallized from ethanol. Yield: 93%; m. p. 253-255 оC; IR (KBr, cm-
1): 3234 (NH), 3040 (CH-aromatic), 1720 (C=O), 1156 (C=S); 1H NMR 
(DMSO-d6, 300 MHz): δ 6.83 (s, 1H, =CH), 7.03-7.18 (m, 2H, Ar-H), 
7.24-7.81 (m, 4H, Ar-H), 7.84-7.86 (d, 1H, J=5.1Hz, Ar-H), 7.94-7.95 
(d, 1H, J=4.2 Hz, Ar-H), 12.40 (s, 1H, NH, D2O exchangeable); MS 
m/z: 286 (M+);Anal. Calcd. For C14H10N2OS2 
General procedure for the synthesis of compounds (3a, c) 
(286.37): C, 58.72; H, 
3.52; N, 9.78. Found: C, 58.84; H, 3.57; N, 9.94.  
To a suspension of compounds 2a, c (10 mmol) in aqueous sodium 
hydroxide (12.60 %, 3.5 ml) at room temperature, methanol (25 ml) 
was added and the mixture was stirred until it become clear. Methyl 
iodide (1.56 g, 11 mmol) was added, and the mixture was stirred for 
12 h at room temperature. The separated yellow solid was collected 
by filtration and crystallized from methanol. 
Synthesis of 2-(methylthio)-1-phenyl-4-(thiophen-2-yl 
methylene)-1H-imidazol-5(4H)-one (3a)  
Yield: 92 %; m. p. 130-132 оC; IR (KBr; cm-1): 3032 (CH aromatic), 
2917 (CH aliphatic), 1723 (C=O);1H NMR (DMSO-d6, 300 MHz): δ 
2.49 (s, 3H, CH3), 7.17 (s, 1H, =CH), 7.19-7.20 (m, 2H, Ar-H), 7.35-
7.43 (m, 1H, Ar-H), 7.50-7.57 (m, 3H, Ar-H), 7.70-7.72 (d, 1H, J=3.3 
Hz, Ar-H), 7.88-7.90 (d, 1H, J=5.1Hz, Ar-H);[13]C NMR (DMSO-d6, 75 
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MHz): δ 12.98(CH3), 115.46 (=CH), 117.28 (=CH), 126.36 (=CH), 
127.54 (=CH), 128.53 (=CH), 129.38 (=CH), 132.36 (-C=), 135.50 (-
C=), 137.65 (-C=), 163.54 (C=N), 167.30 (C=O); m/z: 300 (M+);Anal. 
Calcd. For C15H12N2OS2
Synthesis of 2-(methylthio)-4-(4-nitrobenzylidene)-1-phenyl-
1H-imidazol-5(4H)-one (3c)  
 (300.40): C, 59.97; H, 4.03; N, 9.33. Found: 
C, 60.12; H, 4.09; N, 9.48.  
Yield: 72 %; m. p. 140-142 оC; IR (KBr, cm-1): 3050 (CH aromatic), 
2925 (CH aliphatic), 1725 (C=O), 1502, 1339 (NO2);1H NMR (DMSO-
d6, 300 MHz): δ 2.73 (s, 3H, CH3), 7.06 (s, 1H, =CH), 7.43-7.56 (m, 3H, 
Ar-H), 8.14-8.17 (d,1H, J=8.4Hz, Ar-H), 8.28-8.38 (m, 3H, Ar-H), 8.50-
8.85 (m, 2H, Ar-H); m/z: 339 (M+); Anal. Calcd. For C17H13N3O3
General procedure for the synthesis of compounds (4a-h) 
S 
(339.37): C, 60.17; H, 3.86; N, 12.38. Found: C, 60.29; H, 3.83; N, 12.51.  
A mixture of compounds 3 a-c (1 mmol) and the appropriate amine 
(2 ml) was heated under reflux for 1 h, after cooling and dilution 
with water, the precipitate was collected and crystallized from 
ethanol to give yellow crystals of 4a-h. 
Synthesis of 1-phenyl-2-(phenylamino)-4-(thiophen-2-
ylmethylene)-1H-imidazol-5(4H)-one (4a) 
Yield 75 %; m. p. 255-257 оC; IR (KBr, cm-1): 3292 (NH), 3100 (CH 
aromatic), 1730 (C=O);1HNMR (DMSO-d6, 300 MHz): δ 6.73(s, 1H, 
=CH), 6.75-7.08 (m, 3H, Ar-H), 7.60-7.78 (m, 5H, Ar-H), 7.78-7.89 (m, 
5H, Ar-H) and 9.61 (s, 1H, NH, D2O exchangeable); m/z: 345 (M+); 
Anal. Calc. For C20H15N3
Synthesis of 2-(cyclohexylamino)-1-phenyl-4-(thiophen-2-
ylmethylene)-1H-imidazol-5(4H)-one (4b) 
OS (345.42): C, 69.54; H, 4.38; N, 12.17. 
Found: C, 69.78; H, 4.44; N, 12.35.  
Yield 79 %; m. p. 188-190 оC; IR (KBr, cm-1): 3314 (NH), 3064 (CH 
aromatic), 2926, 2851 (CH aliphatic), 1716 (C=O); 1HNMR (DMSO-
d6, 300 MHz): δ 1.29-2.08 (m, 11H, aliphatic H), 3.90 (s, 1H, NH, D2O 
exchangeable), 6.82 (s, 1H, =CH), 6.95-6.98 (d, 1H, J=7.8Hz, Ar-H), 




OS (351.47): C, 68.35; H, 6.02; N, 11.96. Found: C, 
68.08; H, 6.06; N, 12.03. 
Yield 79 %; m. p: 283-285 оC; IR (KBr, cm-1): 3405 (NH), 3035 (CH 
aromatic), 2923, 2831 (CH aliphatic), 1722 (C=O); 1HNMR (DMSO-
d6, 300 MHz): δ 3.76 (s, 3H, OCH3), 6.93 (s, 1H, =CH), 6.96-7.95 (m, 




S (375.44): C, 67.18; H, 4.56; N, 11.19. Found: C, 67.26; 
H, 4.60; N, 11.28. 
Yield 75 %; m. p. 220-222 оC; IR (KBr, cm-1): 3208 (NH), 3066 (CH 
aromatic), 2920 (CH aliphatic), 1723 (C=O); 1HNMR (DMSO-d6, 300 
MHz): δ 2.23 (s, 3H, CH3), 6.82 (s, 1H, =CH), 7.03-7.92 (m, 12H, Ar-H), 




(359.44): C, 70.17; H, 4.77; N, 11.69. Found: C, 70.31; H, 4.82; N, 11.87. 
Yield 83%; m. p.170-173; IR (KBr, cm-1): 3071(CH aromatic), 2930, 
2852 (CH aliphatic), 1719 (C=O); 1HNMR (DMSO-d6, 300 MHz): δ 
0.72-1.14 (m, 4H, 2CH2), 1.42-150 (m, 6H, 3CH2), 6.94 (s, 1H, =CH), 
7.09-7.11 (t, 1H, J=3.6, 5.1Hz, Ar-H), 7.37-7.68 (m, 7H, Ar-H); m/z: 
337 (M+); Anal. Calcd. For C19H19N3
Synthesis of 2-morpholino-1-phenyl-4-(thiophen-2-yl 
methylene)-1H-imidazol-5(4H)-one (4f) 
OS (337.44): C, 67.63; H, 5.68; N, 
12.45. Found: C, 67.71; H, 5.76; N, 12.62.  
Yield 80%; m. p. 180-182 оC; IR (KBr, cm-1): 3064 (CH aromatic), 
2954, 2915 (CH aliphatic), 1712 (C=O); 1HNMR (DMSO-d6, 300 
MHz): δ 3.43-3.57 (m, 8H,CH2), 7.02 (s, 1H, =CH), 7.11-7.70 (m, 8H, 
Ar-H); m/z: 339 (M+); Anal. Calcd. For C18H17N3O2
Synthesis of 4-(4-chlorobenzylidene)-1-phenyl-2-(piperidin-1-
yl)-1H-imidazol-5(4H)-one (4g) 
S (339.41): C, 
63.70, H, 5.05; N, 12.38. Found: C, 63.91; H, 5.09; N, 12.52.  
Yield 75 %; m. p. 220-222 оC; IR (KBr, cm-1): 3058 (CH aromatic), 
2989, 2936 (CH aliphatic), 1729 (C=O), 800 (C-Cl); 1HNMR (DMSO-
d6, 300 MHz): δ 1.45-1.54 (m, 10H, 5CH2), 6.56 (s, 1H, =CH), 7.38-




O (365.86): C, 68.94; H, 5.51; N, 11.49. Found: C, 68.92; H, 
5.78; N, 11.25.  
Yield 70%; m. p. 245-247 оC; IR (KBr, cm-1): 3059 (CH aromatic), 2932, 
2854 (CH aliphatic), 1663 (C=O), 1514, 1320 (NO2); 1HNMR (DMSO-
d6, 300 MHz): δ 0.83-2.11 (m, 10H, 5CH2), 6.47 (s, 1H, =CH), 6.52-8.95 
(m, 9H, Ar-H); m/z: 376 (M+); Anal. Calcd. For C21H20N4O3 
General procedure for the synthesis of compounds (5a-c) 
(376.41): C, 
67.01; H, 5.36; N, 14.88. Found: C, 67.13; H, 5.42; N, 15.04.  
A suspension of 3a-c (10 mmol) in absolute ethanol (20 ml) and 
hydrazine hydrate (2 ml) was heated under reflux for 1 h until the 
starting material was consumed [TLC, Ethyl acetate: Petroleum ether 
(60:80о
Synthesis of 2-hydrazinyl-1-phenyl-4-(thiophen-2-yl 
methylene)-1H-imidazol-5(4H)-one (5a) 
C), (3:2)]. The separated yellow solid after cooling was 
filtered and crystallized from ethanol. 
Yield 83%; m. p. 210-212 оC; IR (KBr, cm-1): 3357, 3312 (NH2), 3253 
(NH), 3083 (CH aromatic), 1724 (C=O);1HNMR (DMSO-d6, 300 MHz): δ 
5.32 (s, 2H, NH2, D2O exchangeable), 7.02 (s, 1H, =CH), 7.05-7.13 (m, 2H, 
Ar-H), 7.36-7.41 (t, 2H, J=8.1, 7.5Hz, Ar-H), 7.47-7.49 (d, 1H, J=3.3Hz, Ar-
H), 7.72-7.74 (d, 1H, J=5.1Hz, Ar-H), 8.15-8.17 (d, 2H, J=7.8Hz, Ar-H), 9.37 
(s, 1H, NH, D2O exchangeable);13CNMR (DMSO-d6, 75 MHz): 110.89 
(=CH), 119.41(=CH), 122.83 (=CH), 127 (=CH), 128 (=CH), 130.80 (=CH), 
130.86 (-C=), 135.49 (-C=), 138.37 (O=C-CN=), 153.92 (C=N), 166.99 
(C=O); m/z: 284 (M+); Anal. Calcd. For C14H12N4
Synthesis of 4-(4-chlorobenzylidene)-2-hydrazinyl-1-phenyl-
1H-imidazol-5(4H)-one (5b) 
OS (284.34): C, 59.14; H, 
4.25; N, 19.70. Found: C, 59.23; H, 4.31; N, 19.86.  
Yield 60%; m. p. 270-272оC; IR (KBr, cm-1): 3378, 3301 (NH2), 3179 
(NH), 3070 (CH aromatic), 1727 (C=O), 810 (C-Cl);1HNMR (DMSO-d6, 
300 MHz): δ 5.40 (s, 2H, NH2, D2O exchangeable), 7.12 (s, 1H, =CH), 7.42-
7.48 (t, 2H, J=7.8, 8.1Hz, Ar-H), 7.57-7.62 (m, 3H, Ar-H), 7.80-7.81 (d, 1H, 
J=7.3Hz, Ar-H), 8.12-8.16 (m, 3H, Ar-H), 9.72 (s, 1H, NH, D2O 




(312.75): C, 61.44; H, 4.19; N, 17.91. Found: C, 61.52; H, 4.17; N, 18.07.  
Yield 60%; m. p. 218-220 оC; IR (KBr, cm-1): 3331, 3287 (NH2), 3208 
(NH), 3070 (CH aromatic), 1724 (C=O), 1504, 1333 (NO2); 1HNMR 
(DMSO-d6,  300 MHz): δ 5.40 (s, 2H, NH2, D2O exchangeable), 6.65 (s, 
1H, =CH), 7.49-7.52 (m, 3H, Ar-H), 7.66-7.73 (m, 4H, Ar-H), 8.14-8.17 
(d, 2H, J=8.4Hz, Ar-H), 10.56 (s, 1H, NH, D2O exchangeable); m/z: 
323 (M+); Anal. Calcd. For C16H13N5O3 
General procedure for the synthesis of compounds (6a-j)  
(323.31): C, 59.44; H, 4.05; N, 
21.66. Found: C, 59.62; H, 4.12; N, 21.79.  
A mixture of equi molecular amounts of compounds 5a-c and the 
appropriate aromatic aldehyde (2 mmol) in glacial acetic acid (5 ml) 
was heated under reflux for 3 h. The reaction mixture was cooled 
and diluted with water (20 ml). The separated solid was filtered and 
crystallized from ethanol.  
Synthesis of 2-benzylidenehydrazinyl-1-phenyl-4-(thiophen-2-
ylmethylene)-1H-imidazol-5(4H)-one (6a) 
Yield 69%; m. p. 220-222 оC; IR (KBr, cm-1): 3421 (NH), 3034 (CH 
aromatic), 1721 (C=O);1HNMR (DMSO-d6, 300 MHz): δ 7.17 (s, 1H, 
Osman et al. 
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=CH), 7.19-7.35 (m, 2H, Ar-H), 7.40-7.55 (m, 9H, Ar-H), 7.70-7.72 (d, 
1H, J=3.6Hz, Ar-H), 7.88-7.90 (d, 1H, J=4.8Hz, Ar-H), 9.43 (s, 1H, 
N=CH), 9.80 (s, 1H, NH, D2O exchangeable); m/z: 374 (M++2), 372 
(M+); Anal. Calcd. For C21H16N4
Synthesis of 2-(4-nitrobenzylidene) hydrazinyl-1-phenyl-4-
(thiophen-2-yl-methylene)-1H-imidazol-5(4H)-one (6b) 
OS (372.44): C, 67.72; H, 4.33; N, 
15.04. Found: C, 67.85; H, 4.41; N, 15.17.  
Yield 82%; m. p. 305-307 оC; IR (KBr, cm-1): 3373 (NH), 3060 (CH 
aromatic), 1700 (C=O), 1509, 1380 (NO2);1HNMR (DMSO-d6, 300 
MHz): δ 7.16-7.18 (m, 3H, Ar-H+=CH), 7.44-7.58 (m, 4H, Ar-H), 7.81-
7.82 (m, 1H, Ar-H), 8.13-8.16 (m, 2H, Ar-H), 8.33-8.40 (m, 3H, Ar-H), 
9.59 (s, 1H, N=CH), 9.87 (s, 1H, NH, D2O exchangeable); 13CNMR 
(DMSO-d6, 75 MHz): 105.47 (=CH), 110.93 (=CH), 110.96 (=CH), 
113.55 (=CH), 121.28 (=CH), 120.97 (=CH), 121.35 (=CH), 124.46 
(=CH), 129.40 (=CH), 130.15 (=CH), 132.58 (-C=), 132.74 (-C=), 
138.71(=C-), 140.46 (C=N), 147.06 (=C-NO2), 175 (C=O); m/z: 417 
(M+); Anal. Calcd. For C21H15N5O3
Synthesis of 2-(4-methoxybenzylidene) hydrazinyl-1-phenyl-4-
(thiophen-2-ylmethylene)-1H-imidazol-5(4H)-one (6c) 
S (417.44): C, 60.42; H, 3.62; N, 
16.78. Found: C, 60.51; H, 3.61; N, 16.87.  
Yield 75%; m. p. 232-234 оC; IR (KBr, cm-1): 3362 (NH), 3070 (CH 
aromatic), 2927, 2863 (CH aliphatic), 1711 (C=O); 1HNMR (DMSO-d6, 
300 MHz): δ 3.85 (s, 3H, OCH3), 6.72 (s, 1H, =CH), 7.05-7.16 (m, 4H, Ar-
H), 7.42-7.47 (t, 1H, J=7.8, 7.2 Hz, Ar-H), 7.56-7.57 (d, 1H, J=3Hz, Ar-H), 
7.63-7.74 (m, 2H, Ar-H), 7.78-7.80 (d, 1H, J=5.1Hz, Ar-H), 7.87-7.89 (d, 
1H, J=7.5Hz, Ar-H), 8.02-8.04 (d, 1H, J=8.1Hz, Ar-H), 8.14-8.17 (d, 1H, 
J=8.4Hz, Ar-H), 9.45 (s, 1H, N=CH), 9.61 (s, 1H, NH, D2O exchangeable); 
m/z: 402 (M+); Anal. Calcd. For C22H18N4O2
Synthesis of 2-(4-methylbenzylidene) hydrazinyl-1-phenyl-4-
(thiophen-2-yl-methylene)-1H-imidazol-5(4H)-one (6d) 
S (402.47): C, 65.65; H, 
4.51; N, 13.92. Found: C, 65.79; H, 4.57; N, 14.06.  
Yield 70%; m. p. 231-233 оC; IR (KBr, cm-1): 3370 (NH), 3081 (CH 
aromatic), 2916 (CH aliphatic), 1705 (C=O); 1HNMR (DMSO-d6, 300 
MHz) (ppm): δ 2.39 (s, 3H, CH3), 7.14-7.16 (m, 3H, Ar-H+=CH), 7.33-
7.36 (m, 5H, Ar-H), 7.42-7.45 (t, 1H, J=3, 8.1 Hz, Ar-H), 7.56-7.57 (d, 
1H, J=2.7Hz, Ar-H), 7.79-7.80 (d, 1H, J=4.8Hz, Ar-H), 7.95-7.98 (d, 1H, 
J=7.8Hz, Ar-H), 8.14-8.17 (d, 1H, J=8.1Hz, Ar-H), 9.45 (s, 1H, N=CH), 
9.64 (s, 1H, NH, D2O exchangeable); m/z: 386 (M+); Anal. Calcd. For 
C22H18N4
Synthesis of 2-(4-chlorobenzylidene) hydrazinyl-1-phenyl-4-
(thiophen-2-yl-methylene)-1H-imidazol-5-(4H)-one (6e) 
OS (386.47): C, 68.37, H, 4.69, N, 14.50. Found: C, 68.46; H, 
4.72; N, 14.72.  
Yield 60%; m. p. 235-237 оC; IR (KBr, cm-1): 3369 (NH), 3067 (CH 
aromatic), 1707 (C=O), 790 (C-Cl); 1HNMR (DMSO-d6, 300 MHz): δ 
7.15-7.17 (m, 3H, Ar-H+=CH), 7.42-7.48 (t, 2H, J=8.1Hz, Ar-H), 7.57-
7.62 (m, 2H, Ar-H), 7.80-7.81 (d, 1H, J=4.8Hz, Ar-H), 8.12-8.16 (m, 
5H, Ar-H), 9.51 (s, 1H, N=CH), 9.72 (s, 1H, NH D2O exchangeable); 
Anal. Calcd. For C21H15Cl N4
Synthesis of 1-phenyl-4-(thiophen-2-ylmethylene)-2-(3,4,5-
trimethoxy-benzylidene)hydrazinyl-1H-imidazol-5(4H)-one (6f) 
OS (406.89): C, 61.99; H, 3.72; N, 13.77. 
Found: C, 62.07; H, 3.68; N, 13.94.  
Yield 80%; m. p. 240-242 оC; IR (KBr, cm-1): 3344 (NH), 3073 (CH 
aromatic), 2935 (CH aliphatic), 1707 (C=O);1HNMR (DMSO-d6, 300 
MHz): δ 3.84 (s, 6H, 2OCH3), 3.90 (s, 3H, OCH3), 7.15-7.17 (m, 3H, 
Ar-H+=CH), 7.41-7.48 (m, 4H, Ar-H), 7.57-7.58 (d, 1H, J=3.3Hz, Ar-H), 
7.81-7.82 (d, 1H, J=4.8Hz, Ar-H), 8.16-8.18 (t, 2H, J=8.1, 6 Hz, Ar-H), 
9.57 (s, 1H, N=CH), 9.63 (s, 1H, NH, D2O exchangeable); m/z: 462 
(M+); Anal. Calcd. For C24H22N4O4
Synthesis of 2-(2-fluorobenzylidene) hydrazinyl-1-phenyl-4-
(thiophen-2-yl-methylene)-1H-imidazol-5(4H)-one (6g) 
S (462.52): C, 62.32; H, 4.79; N, 
12.11. Found: C, 62.44; H, 4.83; N, 12.24.  
Yield 80%; m. p. 218-220 оC; IR (KBr, cm-1): 3372 (NH), 3042 (CH 
aromatic), 1714 (C=O), 755 (C-F); 1HNMR (DMSO-d6, 300 MHz): δ 
7.13-7.17 (m, 4H, Ar-H+=CH), 7.37-7.41 (m, 5H, Ar-H), 7.80-7.82 (d, 
1H, J=4.8Hz, Ar-H), 8.14-8.16 (d, 2H, J=8.1Hz, Ar-H), 8.36-8.41(t, 1H, 
J=6, 9Hz, Ar-H), 9.50 (s, 1H, N=CH), 9.96 (s, 1H, NH, D2O 
exchangeable); m/z: 390 (M+); Anal. Calcd. For C21H15FN4
Synthesis of 4-(4-chlorobenzylidene)-1-phenyl-2-(3,4,5-
trimethoxy-benzylidene) hydrainyl-1H-imidazol-5(4H)-one (6h) 
OS (390.43): 
C, 64.60; H, 3.87; N, 14.35. Found: C, 64.78; H, 3.89; N, 14.48.  
Yield 80%; m. p. 240-242 оC; IR (KBr, cm-1): 3379 (NH), 3069 (CH 
aromatic), 2938, 2834 (CH aliphatic), 1720 (C=O), 820 (C-
Cl); 1HNMR (DMSO-d6, 300 MHz): δ 3.84 (s, 6H, 2 OCH3), 3.89 (s, 3H, 
OCH3), 6.71 (s, 1H, =CH), 7.17-8.21 (m, 12H, Ar-H+N=CH), 9.60 (s, 
1H, NH, D2O exchangeable); m/z: 491/493 (M+/M++2); Anal. Calcd. 
For C26H23ClN4O4
Synthesis of 2-(4-methoxybenzylidene) hydrazinyl-4-(4-
nitrobenzylidene)-1-phenyl-1H-imidazol-5(4H)-one (6i) 
 (490.94): C, 63.61; H, 4.72; N, 11.41. Found: C, 
63.79; H, 4.79; N, 11.56.  
Yield 75%; m. p. 231-233 оC; IR (KBr, cm-1): 3361 (NH), 3001 (CH 
aromatic), 2927 (CH aliphatic), 1698 (C=O), 1570,1330 (NO2);1HNMR 
(DMSO-d6, 300 MHz): δ 3.85 (s, 3H, OCH3), 6.69-6.71 (d, 1H, J=6.6, Ar-
H), 6.77 (s, 1H, =CH), 7.07-9.57 (m, 13H, Ar-H+CH=N), 9.77 (s, 1H, NH, 
D2O exchangeable); Anal. Calcd. For C24H19N5O4 
Synthesis of 4-(4-nitrobenzylidene)-1-phenyl-2-(3,4,5-trimethoxy–
benzylidene) hydrazinyl)-1H-imidazol-5(4H)-one (6j) 
(441.44): C, 65.30; H, 
4.34; N, 15.86. Found: C, 65.47; H, 4.41; N, 16.02.  
Yield 80%; m. p. 271-273 оC; IR (KBr, cm-1): 3368 (NH), 3066 (CH 
aromatic), 2934 (CH aliphatic), 1657 (C=O), 1571, 1329 
(NO2);1HNMR (DMSO-d6, 300 MHz): δ 3.84 (s, 6H, 2OCH3), 3.89 (s, 
3H, OCH3), 6.66 (s, 1H, =CH), 7.18-8.29 (m, 11H, Ar-H), 9.50 (s, 1H, 
N=CH), 9.60 (s, 1H, NH, D2O exchangeable); Anal. Calcd. For 
C26H23N5O6 
General procedure for the synthesis of compounds (7a-c) 
(501.49): C, 62.27; H, 4.62; N, 13.97. Found: C, 62.39; H, 
4.69; N, 14.14. 
Compounds 5a-c (4 mmol) was stirred with isatin (0.59 g, 4 mmol) 
in acetic acid (5 ml) overnight at room temperature. The separated 
solid was filtered and crystallized from ethanol as yellow crystals. 
Synthesis of 3-(5-oxo-1-phenyl-4-(thiophen-2-ylmethylene)-
4,5-dihydro-1H-imidazol-2-yl)hydrazono-indolin-2-one (7a) 
Yield 85%; m. p. 260-262 оC; IR (KBr, cm-1): 3358 (NH), 3312 (NH), 
3087 (CH aromatic), 1725 (C=O), 1655 (C=O); 1HNMR (DMSO-d6, 
300 MHz): δ 5.32 (s, 1H, NH, D2O exchangeable), 7.02 (s, 1H, =CH), 
7.07-7.13 (m, 5H, Ar-H), 7.36-7.41 (t, 2H, J=7.8Hz, Ar-H), 7.47-7.48 
(d, 2H, J=3.3Hz, Ar-H), 7.72-7.74 (d, 1H, J=5.1Hz, Ar-H), 8.15-8.17 (d, 
2H, J=7.8Hz, Ar-H), 9.37 (s, 1H, NH, D2O exchangeable); Anal. Calcd. 
For C22H15N5O2
Synthesis of 3-(4-(4-chlorobenzylidene)-5-oxo-1-phenyl-4,5-
dihydro-1H-imidazol-2-yl) hydrazono)indolin-2-one (7b) 
S (413.45): C, 63.91; H, 3.66; N, 16.94. Found: C, 
64.08; H, 3.63; N, 17.12.  
Yield 80%; m. p. 140-142 оC; IR (KBr, cm-1): 3349 (NH), 3200 (NH), 
3073 (CH aromatic), 2925 (CH aliphatic), 1719 (C=O), 1661 (C=O), 
810 (C-Cl);1HNMR (DMSO-d6, 300 MHz): δ 5.35 (s, 1H, NH D2O 
exchangeable), 6.63 (s, 1H, =CH), 6.81-6.97 (m, 2H, Ar-H), 7.10-7.18 
(m, 2H, Ar-H), 7.28-7.30 (d, 1H, J=7.5Hz, Ar-H), 7-38-7.62 (m, 2H, Ar-
H), 7.93-8.04 (m, 6H, Ar-H), 9.5 (s, 1H, NH D2O exchangeable); m/z: 
441/443 (M+/M++2); Anal. Calcd. For C24H16 ClN5O2
Synthesis of 3-(4-(4-nitrobenzylidene)-5-oxo-1-phenyl-4,5-
dihydro-1H-imidazol-2-yl) hydrazono)indolin-2-one (7c) 
 (441.87): C, 
65.24; H, 3.65; N, 15.85. Found: C, 65.42, H, 3.60, N, 16.04.  
Yield 70%; m. p. 138-140 оC; IR (KBr, cm-1): 3348 (NH), 3302 (NH), 
3000 (CH aromatic), 2925 (CH aliphatic), 1717(C=O), 1659(C=O), 
1502, 1335 (NO2); 1HNMR (DMSO-d6, 300 MHz): δ 5.40 (s, 1H, NH 
D2O exchangeable), 6.70 (s, 1H, =CH), 6.81-8.39 (m, 13H, Ar-H), 9.75 
(s, 1H, NH D2O exchangeable); m/z: 452 (M+); Anal. Calcd. For 
C24H16N6O4 
General procedure for the synthesis of compounds (8a-c) 
(452.42): C, 63.71; H, 3.56; N, 18.58. Found: C, 63.86; H, 
3.53; N, 18.72.  
Compounds 5a-c (4 mmol) was stirred with p-toluene sulfonyl 
chloride (0.76 g, 4 mmol) in acetic acid (10 ml) overnight at room 
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Int J Pharm Pharm Sci, Vol 7, Issue 10, 36-45 
 
39 
temperature in the presence of anhydrous sodium acetate (0.41 gm, 
5 mmol). The separated solid was filtered and crystallized from 




Yield 80%; m. p. 155-157 оC; IR (KBr, cm-1): 3247 (NH), 3149 (NH), 
3050 (CH aromatic), 2981 (CH aliphatic), 1714 (C=O), 1327, 1152 
(SO2); 1HNMR (DMSO-d6, 300 MHz): δ 2.08 (s, 3H, CH3), 7.11-8.07 
(m, 13H, Ar-H+=CH), 9.54 (s, 1H, NH D2O exchangeable), 10.58 (s, 
1H, NH D2O exchangeable); 13CNMR (DMSO-d6, 75 MHz): 20.85 
(CH3), 112.29 (=CH), 119.67 (=CH), 123.30 (=CH), 127.24 (=CH), 
128.78 (=CH), 131.55 (=CH), 131.69 (-C=), 134.08 (-C=), 137.99 
(=CH), 138.16 (CN=), 152.03 (C=N), 169.35(C=O); m/z: 438 (M+); 
Anal. Calcd. For C21H18N4O3S2
Synthesis of N’-(4-(4-chlorobenzylidene)-5-oxo-1-phenyl-4,5-
dihydro-1H-imidazol-2-yl)-4-methylbenzenesulfonohydrazide (8b) 
 (438.52): C, 57.52; H, 4.14; N, 12.78. 
Found: C, 57.81; H, 4.22; N, 13.07.  
Yield 70%; m. p. 121-123 оC; IR (KBr, cm-1): 3337 (NH), 3276 (NH), 
3073 (CH aromatic), 2960 (CH aliphatic), 1718 (C=O), 1363, 1154 
(SO2), 820 (C-Cl); 1HNMR (DMSO-d6, 300 MHz): δ 2.07 (s, 3H, CH3), 
6.61 (s, 1H, =CH), 7.07-8.17 (m, 13H, Ar-H), 9.45 (s, 1H, NH D2O 
exchangeable), 10.56 (s, 1H, NH D2O exchangeable); m/z: 467/469 




S (466.94): C, 59.16, H, 
4.10, N, 12.00. Found: C, 59.44; H, 4.17; N, 12.23.  
Yield 60%; m. p. 127-129; IR (KBr, cm-1): 3428(NH), 3338 (NH), 
3055 (CH aromatic), 2926 (CH aliphatic), 1718 (C=O), 1565, 1332 
(NO2), 1332, 1158 (SO2); 1HNMR (DMSO-d6, 300 MHz): δ 2.08 (s, 3H, 
CH3), 6.61 (s, 1H, =CH), 6.68-8.38 (m, 13H, Ar-H), 9.50 (s, 1H, NH 
D2O exchangeable), 9.69 (s, 1H, NH D2O exchangeable); m/z: 477 
(M+); Anal. Calcd. For C23H19N5O5
General procedure for the synthesis of compounds (9a, b)  
S (477.49): C, 57.85; H, 4.01; N, 
14.67. Found: C, 58.03; H, 4.06; N, 14.91.  
Compound 5a (0.284 g, 1 mmol) was refluxed with the appropriate 
acid chloride (1 mmol) in pyridine (10 ml) for 5 h. The reaction 
mixture was poured on crushed ice. The product was filtered and 
crystallized from ethanol as yellow crystals. 
Synthesis of N'-(5-oxo-1-phenyl-4-(thiophen-2-ylmethylene)-
4,5-dihydro-1H-imidazol-2-yl) acetohydrazide (9a) 
Yield 60%; m. p. 290-292 оC; IR (KBr, cm-1): 3258 (2 NH), 3080 (CH 
aromatic), 2984 (CH, aliphatic), 1720 (C=O), 1654 (C=O); 1HNMR 
(DMSO-d6, 300 MHz): δ 2.01 (s, 3H, CH3), 7.12-8.08 (m, 9H, Ar-
H+=CH), 9.75 (s, 1H, NH D2O exchangeable), 11.31 (s, 1H, NH D2O 
exchangeable); Anal. Calcd. For C16H14N4O2
Synthesis of 4-chloro-N'-(5-oxo-1-phenyl-4-(thiophen-2-
ylmethylene)-4,5-dihydro-1H-imidazol-2-yl)benzohydrazide (9b) 
S (326.37): C, 58.88; H, 
4.32; N, 17.17. Found: C, 59.06; H; 4.36; N, 17.32. 
Yield 65%; m. p. 285-287 оC; IR (KBr, cm-1): 3303 (2 NH), 3097 (CH 
aromatic), 1709 (C=O), 1653(C=O), 810 (C-Cl); 1HNMR (DMSO-d6, 300 
MHz): δ 7.54-7.57 (m, 6H, Ar-H+=CH), 7.92-7.95 (m, 7H, Ar-H), 13.12 (s, 
2H, 2NH exchangeable); Anal. Calcd. For C21H15 ClN4O2
General procedure for the synthesis of compounds (10a, b)  
S (422.89): C, 
59.64; H, 3.58; N, 13.25. Found: C, 59.76; H, 3.62; N, 13.39.  
Compounds 9a, b (5 mmol) was refluxed in ethanol (20 ml) containing 
10% NaOH (5 ml) for 10 h. After cooling and dilution with water (10 ml), 
the formed solid was filtered and washed with acetic acid. 
Synthesis of 3-methyl-7-phenyl-5-(thiophen-2-ylmethylene)-
5H-imidazo [2,1-c][1,2,4]triazol-6(7H)-one (10a) 
Yield 35%; m. p. 255-257 оC; IR (KBr, cm-1): 3096 (CH aromatic), 
2982 (CH aliphatic), 1716 (C=O); m/z: 308 (M+); Anal. Calcd. For 
C16H12N4
Synthesis of 3-(4-chlorophenyl)-7-phenyl-5-(thiophen-2-yl 
methylene)-5H-imidazo [2,1-c][1,2,4]triazol-6(7H)-one (10b) 
OS (308.36): C, 62.32; H, 3.92; N, 18.17. Found: C, 62.43; H, 
3.97; N, 18.33.  
Yield 40%; m. p. 260-262 оC; IR (KBr, cm-1): 3050 (CH aromatic), 
1683 (C=O), 800 (C-Cl); Anal. Calcd. For C21H13 ClN4
General procedure for the synthesis of compounds (11a-c) 
OS (404.87): C, 
62.30; H, 3.24; N, 13.84. Found: C, 62.47; H, 3.20; N, 14.02.  
Compounds 5a-c (3 mmol) and ethyl chloroformate (2 ml) were 
heated under reflux for 2 h, absolute ethanol (30 ml) was added and 
the reaction mixture was evaporated to half of its volume, then the 
mixture was diluted with absolute ethanol (30 ml) and refluxed with 
potassium hydroxide (0.17 g, 3 mmol) for 4 h. The reaction mixture 
was cooled, acidified with HCl (0.1 N), the separated solid was 
filtered and crystallized from ethanol as yellow crystals. 
Synthesis of 7-phenyl-5-(thiophen-2-ylmethylene)-2H-imidazo 
[2,1-c]-[1,2,4] triazole-3,6(5H,7H)-dione (11a) 
Yield 70%; m. p. 245-247 оC; IR (KBr, cm-1): 3289 (NH), 3100 (CH 
aromatic), 1725 (C=O), 1699 (C=O); 1HNMR (DMSO-d6, 300 MHz): δ 
6.70 (s, 1H, =CH), 7.16-7.73 (m, 8H, Ar-H), 10.41 (s, 1H, NH D2O 
exchangeable); 13CNMR (DMSO-d6, 75 MHz): 103.27 (=CH), 123.71 
(=CH), 124.51 (=CH), 126.83 (=CH), 128 (=CH), 128.8 (=CH), 128.87 
(=CH), 129.56 (-C=), 131.78 (-C=), 135.80 (CN=), 154.51 (C=N), 153.79 
(C=O), 162.91(C=O); m/z: 310 (M+); Anal. Calcd. For C15H10N4O2
Synthesis of 5-(4-chlorobenzylidene)-7-phenyl-2H-imidazo 
[2,1-c][1,2,4] triazole-3,6(5H,7H)-dione (11b) 
S 
(310.33): C, 58.05; H, 3.25; N, 18.05. Found: C, 58.19; H, 3.31; N, 18.21.  
Yield 65%; m. p. 150-152 оC; IR (KBr, cm-1): 3231 (NH), 3023 (CH 
aromatic), 1716 (C=O), 1656 (C=O), 810 (C-Cl);1HNMR (DMSO-d6, 
300 MHz): δ 6.64 (s, 1H, =CH), 6.67-7.73 (m, 9H, Ar-H); 11.11 (s, 1H, 




60.28; H, 3.27; N, 16.54. Found: C, 60.24; H, 3.31; N, 16.63. 
Yield 60%; m. p 140-142 оC; IR (KBr, cm-1): 3335 (NH), 3100 (CH 
aromatic), 1715 (C=O), 1656(C=O); 1521, 1316 (NO2);1HNMR (DMSO-
d6, 300 MHz): δ 7.34-8.22 (m, 10H, Ar-H+=CH), 9.80 (s, 1H, NH D2O 
exchangeable); m/z: 349 (M+); Anal. Calcd. For C17H11 N5O4 
General procedure for the synthesis of compounds (12a-c) 
(349.30): 
C, 58.45; H, 3.17; N, 20.05. Found: C, 58.61; H, 3.14; N, 20.22.  
An aqueous solution of sodium nitrite (5 ml, 5%) was added 
dropwise at 10 о
Synthesis of 4-phenyl-6-(thiophen-2-ylmethylene)-4H-imidazo 
[1,2-d]-tetrazol-5(6H)-one (12a) 
C with stirring over 15 min to compound 5a-c (6 
mmol) in 2N hydrochloric acid (10 ml). The mixture was allowed to 
stand at room temperature for 2 h. The formed precipitate was 
filtered, washed with ethanol and crystallized from ethanol as 
yellow crystals. 
Yield 65%; m. p. 235-237 оC; IR (KBr, cm-1): 3099 (CH aromatic), 
1657(C=O); 1HNMR (DMSO-d6, 300 MHz): δ 7.00-8.00 (m, 9H, Ar-H 
and =CH); Anal. Calcd. For C14H9N5
Synthesis of 6-(4-chlorobenzylidene)-4-phenyl-4H-imidazo 
[1,2-d]-tetrazol-5(6H)-one (12b) 
OS (295.32): C, 56.94; H, 3.07; N, 
23.71. Found: C, 57.06; H, 3.04; N, 23.97.  
Yield 60%; m. p. 150-152 оC; IR (KBr, cm-1): 3060 (CH aromatic), 
1647(C=O), 790 (C-Cl); 1HNMR (DMSO-d6, 300 MHz): δ 6.47 (s, 1H, 
=CH), 6.96-8.77 (m, 9H, Ar-H); m/z: 323/325 (M+/M++2); Anal. 
Calcd. For C16H10 ClN5O 
Synthesis of 6-(4-nitrobenzylidene)-4-phenyl-4H-imidazo [1,2-
d]tetrazol-5(6H)-one (12c) 
(323.74): C, 59.36; H, 3.11; N, 21.63. Found: 
C, 59.50; H, 3.17; N, 21.80.  
Yield 50%; m. p. 130-132 оC; IR (KBr, cm-1): 3059 (CH aromatic), 
1648(C=O), 1553, 1308 (NO2); 1HNMR (DMSO-d6, 300 MHz): δ 6.95 
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(s, 1H, =CH), 7.24-8.61 (m, 9H, Ar-H); m/z: 334 (M+); Anal. Calcd. For 
C16H10 N6O3
MCF-7 breast cancer and HCT-116 colon cancer cell lines were 
obtained from the National Cancer Institute, Cairo, Egypt. Potential 
cytotoxicity of the newly obtained derivatives was tested using the 
method of Skehan et al.[18]. Cells were plated in 96-multiwell plate 
(5 x 10
 (334.29): C, 57.49; H, 3.02; N, 25.14. Found: C, 57.62; H, 
3.05; N, 25.22.  
Evaluation of cytotoxic activity 
3cells/well) for 24 h before treatment with the tested 
compounds to allow attachment of cell to the wall of the plate. 
Different concentrations of the tested compounds (0, 5, 12.5, 25 and 
50 µg/ml) were added to the cell monolayer triplicate wells 
prepared for each individual dose. Monolayer cells were incubated 
with the compounds for 48 h at 37оC under a 5% CO2 atmosphere. 
The culture was fixed with cold trichloroacetic acid and stained with 
0.4% Sulphorhodamine-B stain (SRB) dissolved in 1% acetic acid. 
Excess stain was washed with acetic acid and attached stain was 
recovered with Tris EDTA buffer and the color intensity was 
measured in an ELISA reader. The relation between surviving 
fraction and drug concentration is plotted to get the survival curve 
of each tumor cell line of the specified compound. IC50
Molecular docking 
 values were 
calculated from the calibration curve.  
The ligands were sketched and subjected to geometry optimization 
by running energy minimization using Sybyl x1.1 (2010) program 
suite. Parameters of energy minimization as follows: Charges: 
Gasteiger-Marsili Charges; Force Field: Tripos; Termination: 
Gradient energy change, 01.1 Kcal; RMS displacement: 0.001 Å; Non-
bonded cutoff: 8.000 Å; Dielectric function: distant dependent; 
Dielectric constant: 1.00; Iteration: 100. The crystal structure of 
epidermal growth factor receptor with erlotinib (TarcevaTM
 
) (PDB 
code: 1M17) and the crystal structure of CDK2 in complex with ATP 
(PDB code: 1HCK) were retrieved from the protein data bank (PDB). 
Ligands were docked into the receptor active site of both epidermal 
growth factor receptor (EGFR) and cyclin dependent kinase 2(CDK2) 
along with EGFR inhibitor and ATP respectively. Docking of the 
ligands was performed using Gold suite v5.2.0 (2010). In the docking 
process of EGFR, erlotinib and water molecules except HOH10 were 
removed from the binding site. Concerning docking job using CDK2, 
ATP and Mg metal was removed. Other parameters were set as 
default according to gold suite docking protocol. 
Table 1: Evaluation of cytotoxic activity of the newly synthesized compounds against breast carcinoma (MCF7) and colon carcinoma 
(HCT116) cell lines 
Compound  IC50(µg/ml)  a 
(MCF-7) (HCT116) 
2a 3.7 9.83 
3b 4.1 6.98 
4h 10.3 12.4 
5c 3.3 4.73 
6b 12.1 11.9 
6f 4.7 NAPb 
6h 4.1 NAPb 
6j 4.7 NAPb 
10b 4.3 4.73 
11aDoxorubicin  4.70.426  5.330.471 
P
a
PICR50 Ris a dose required to inhibit the cell growth by 50%, Pb PNA = no activity (i.e. ICR50R values are higher than 12.5 µg/ml) 
 
Table 2: Antibacterial activity of the newly synthesized compounds using cup plate diffusion method 
Compounds Diameter (mm) of inhibition zones against the corresponding standard strains of different microorganisms 





















4b - - - 23 23 22 22 
4f - - - 22 23 22 23 
4g 24 25 25 24 25 25 26 
4h - - - - - - - 
5a 22 23 25 27 26 26 25 
5c 20 19 22 26 25 26 25 
6c - - - - - - - 
6f - - - 30 31 30 32 
6h - - - 16 16 16 17 
6j 18 17 18 17 17 18 18 
6k 22 23 22 26 25 25 26 
7a 11 12 11 30 32 30 30 
7b 16 16 17 26 26 26 27 
10a 30 29 28 25 26 26 25 
10b 17 16 17 21 20 20 20 
11a 27 28 27 24 25 25 24 
11b 20 21 20 25 25 25 26 
11c 30 29 32 26 26 25 25 
12a - - - 30 30 31 31 
12b - - - - - - - 
Cefotaxime 
(control) 




25 23 30 25 27 28 30 
DMF(control) - - - - - - - 
Each cup is filled with 100 microliters from each sample; Conc. of each sample is 50 mg/ml. 
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The used bacterial cultures were obtained from Microbiology 
Department, Faculty of Pharmacy, Zagazig University. The newly 
synthesized compounds were tested for their in vitro antibacterial 
activity, in comparison to Cefotaxime and Sulpha-methoxazole as 
reference drugs using the standard agar cup diffusion method 
[19]. Bacterial strains were individually cultured for 48 h in 100 
ml conical flasks containing 30 ml Nutrient Agar (NA). Assay was 
done in 10 cm sterile Petri dishes in which one ml bacterial 
suspension and 15 ml of NA were poured. Plates were shaken 
gently to homogenize the contents. After solidification of the 
media, 5 mm cavities were cut in the solidified agar (4 
cavities/plate) using the sterile cork borer. The test compounds 
and the reference drugs were dissolved in dimethyl formamide 
(DMF) (100 µmol/ml) and were pipette in the cavities. In addition, 
other cavities were pipette with DMF and served as a negative 
control. The seeded plates were incubated at 28±2о
 
C for 48 h. The 
radii of inhibition zones (in mm) of triplicate sets were measured 
and the results are cited in table 2. 
Table 3: Antifungal activity of the newly synthesized 




Candida albicans ATCC 
10231 
4b 26 25 
4f 19 18 
4g 25 25 
4h 23 22 
5a 17 16 
5c 20 19 
6c 29 28 
6f 31 30 
6h 25 26 
6j 24 25 
6k 20 21 
7a 28 27 
7b 29 28 
10a 32 31 
10b - - 
11a 25 24 
11b 26 25 
11c 26 20 
12a 26 25 







Each cup is filled with 100 micro liters from each sample; Conc. of 
each sample is 50 mg/ml. 
 
Antifungal activity  
The used Sabouraud Agar (SA) media were prepared in 
Microbiology Department, Faculty of Pharmacy, Zagazig University. 
The test compounds were evaluated for their antifungal activity in 
vitro, in comparison to Nystatin as a reference drug using the agar 
cup diffusion method [20] against two fungal strains: Aspragillus 
niger (ATCC 16404) and Candida albicans (ATCC 10231). Spore 
suspensions in sterile distilled water were prepared from 7 d old 
culture of the test fungi growing on Sabouraud's dextrose broth (30 
ml) media in 100 ml conical flasks. The final spore concentration was 
nearly 5x104 spores/ml. About 15 ml of the growth medium was 
introduced on sterilized Petri dishes of 10 cm diameter and inoculated 
with 1 ml of spore suspension. Plates were shaken gently to 
homogenize the inocula. After solidification of the media, 5 mm 
cavities were cut in the solidified agar (4 cavities/plate) using sterile 
cork borer and was filled with the solutions of the test compounds and 
Nystatin (100 µmol/ml in DMF). In addition, other cavities were 
impregnated with solvent (DMF) and served as a negative control. The 
seeded plates were incubated at 28±2 о
RESULTS AND DISCUSSION 
C for 7 d. The radii of inhibition 
zones (in mm) of triplicate sets were measured at successive intervals 
during the incubation period and the results are cited in table 3. 
Chemistry 
The novel imidazole and fused imidazole derivatives were 
synthesized as illustrated in schemes 1, 2 and 3: 
3-Phenyl-2-thioxoimidazolidin-4-one (1) was prepared by heating 
glycine and phenyl isothiocyanate in glacial acetic acid containing 
potassium hydroxide for 2 h according to the reported procedure 
[14, 15]. 
5-Arylidine-3-phenyl-2-thioxoimidazolidin-4-ones (2a-c) were 
obtained via stirring compound 1 with different aldehyde 
derivatives in ethanol containing piperidine at room temperature for 
12 h according to the reported procedure [16,17]. 
Alkylation of compounds 2a-c using methyl iodide in methanol 
containing sodium hydroxide gave the thioether derivatives 3a-c. 
Aminolysis of compounds 3a-c with different primary and secondary 
amine derivatives afforded compounds 4a-h. On the other hand, 
hydrazinolysis of thio ethers 3a-c using hydrazine hydrate in 
refluxing ethanol gave 2-hydrazino derivatives 5a-c, the key 
intermediates [21-24] (Scheme 1). 
 
 
Scheme 1: Synthesis of target compounds 1-5 
 
Condensation of the 2-hydrazino derivatives with different aromatic 
aldehydes afforded the proposed hydrazone derivatives 6a-j in good 
yields via refluxing in glacial acetic acid for 3 h [25]. Also, the novel 
compounds 7a-c was obtained in good yield through the reaction of 
the 2-hydrazino derivatives 5a-c with isatin in acetic acid at room 
temperature overnight. However, stirring the 2-hydrazino 
derivatives with p-toluene sulfonyl chloride in acetic acid containing 
anhydrous sodium acetate overnight, afforded 4-methyl benzene 
sulfone hydrazide derivatives 8a-c (Scheme 2). 
Cyclo condensation of compound 5a using acetyl chloride or p-
chlorobenzoyl chloride did not afford the target 3-substituted-7-
phenyl-5-(thiophen-2-yl-methylene)5H-imidazo[2,1-c][1,2.4]triazol-
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6(7H)-ones (10a, b). Instead, N-acylated compounds 9a, b was 
obtained respectively. Structure elucidation of compounds 9a, b was 
achieved using IR, 1
 
HNMR and elemental analysis. The desired 
compounds 10a, b was achieved by refluxing compounds 9a, b in 
ethanol containing sodium hydroxide for 10 h. 
 
Scheme 2: Synthesis of the target compounds 6-8 
 
In addition the novel 5-arylidene-7-phenyl-imidazo [2,1-c][1,2,4]-
triazole-3,6-diones 11a-c were obtained through cyclization of the 2-
hydrazino derivatives 5a-c using ethyl chloroformate in refluxing 
ethanol for 6 h. Finally, treating compounds 5a-c with nitrous acid in 
ice bath for 15 min then stirring at room temperature for 2h lead to 
the novel 6-arylidene-4-phenyl-4H-imidazo[1,2-d]tetrazol-5(6H)-
ones 12a-c (Scheme 3). 
 
 
Scheme 3: Synthesis of the target compounds 9-12 
 
Evaluation of cytotoxic activity 
From the newly synthesized compounds, only ten compounds 2a, 3b, 
4h, 5c, 6b, 6f, 6h, 6j, 10b and 11a were be selected to be evaluated 
for their cytotoxicity against human breast carcinoma (MCF7) cell 
line and colon carcinoma (HCT116) cell line using Skehan et al. 
method [18]. The inhibitory activities were presented as micromolar 
concentrations of the compound that cause 50 % inhibition per unit 
of enzyme (IC50
By investigating the variation in selectivity of the tested compounds 
over the cell lines, it was noticed that most of the compounds under 
investigation showed significant activity against the breast cancer 
cell line (MCF7). On the other hand, only compounds 2a, 3b, 5c, 10b 
and 11a showed significant activity against the colon cancer cell line 
(HCT116). The agreement between the selected compounds in the 
activity against breast cancer (MCF7) cells could be related to the 
common structural feature 3-phenyl-4-imidazolidinone core with 
hydrogen bonding acceptor group at position 2 while the variation 
in selectivity over breast cancer (MCF7) and colon cancer cells 
(HCT116) is probably caused by the differences in the hydrogen 
bonding moiety, hydrocarbon and heterocyclic skeleton around the 
core structure (3-phenyl-4-imidazolidinone). However, the 
hydrazino moiety in compound 5c showed higher activity compared 
with thio, piperidyl, arylidene-hydrazine fragments in compounds 
2a, 4h and 6h respectively. More interestingly compound 5c showed 
the highest activity against the both cell lines (3.3µg/ml and 
4.73µg/ml respectively). On the contrary, compound 3b exhibited 
moderate activity against colon carcinoma cell line (IC
) under the assay condition. Results of cancer 
cellular assays are shown in table 1.  
50
According to the antitumor activity results and structural variation, the 
minimal structural requirements for antitumor activity may be as 
follows; aromatic ring separated by an average distance, a hydrophobic 
moiety directly attached to the basic centre, and a H-bonding acceptor 
(carbonyl group) attached to H-donor urea fragment. This 
pharmacophoric postulation was in consistence with the reported 
results for other antitumor azolidine pharmacophore [26].  
=6.98 
µg/ml), however, the hydrazones 6f, 6h and 6j devoid of any activity 
against the same cell line. Out of the tested compounds, 4h and 6b 
have least activity against the two cell lines. On the other hand, fused 
imidazole derivatives 10b and 11a have high cytotoxic activity 
against the two cell lines indicating the importance of 
imidazotriazol-6-one and imidazotriazole 3,6-dione moieties. 
Molecular docking 
Based on the promising anticancer activities and in order to predict 
if the targets have analogous binding mode to the EGFR and CDK2 
inhibitors, we perform molecular docking into the ATP binding site 
of EGFR and CDK2 assuming that the most active target compounds 
5c and 10b might demonstrate antiproliferative activity against 
breast cancer (MCF-7) and colon cancer (HCT116) cell lines through 
inhibition of EGFR and CDK2 respectively.  
These docking studies illustrated that compound 5c (Fig.1) interacts 
with EGFR-TK in a fashion similar to erlotinib where the 
imidazolidin-5-one scaffold binds to a narrow hydrophobic pocket in 
the N-terminal domain of EGFR-TK forming interaction with Ala719, 
Leu668, Leu694, Val702 and Leu820 residues. The essential interactions 
were conserved between compound 5c and EGFR-TK where the NH of 
hydrazino group at position 2 of imidazolidin-5-one ring interacts with 
the backbone NH of Met-769 via a hydrogen bond (2.46oA). Also, a water 
(HOH-10) molecule-mediated hydrogen bonding interaction is observed 
between the N-1 of the imidazolidin-5-one ring (2.83oA), THr766 
(2.12oA) and the Thr-830 (2.97oA) side chains. Other important 
hydrophobic interactions appeared between phenyl moiety at position 1 
of imidazolidin-5-one ring and Leu694, Leu768, Leu769, Pro770, 
Phe771, Gly772 and Cyc773 amino acids. Also, p-nitrobenzylidene 
moiety at position 4 of imidazolidin-5-one ring interacts with 
hydrophobic side chains of Val702, Ala719, Lys771, Met742, Leu753, 
Leu764, ILeu765 and THr766.  
This mode of binding would also demonstrate the lower activity of 
other imidazolidin-5-ones compared to 5c where the sulfur atom for 
compounds 2a, 3b and nitrogen atom for the hydrazone compounds 
6b, 6f, 6h and 6j at position 2 are less situated to hydrogen bonds NH 
of Met-769 due to steric effect. 
On the other hand, when compound 5c was docked into the active 
binding site of cyclin dependent kinase 2 (CDK2) (fig. 2), the 
imidazolidin-5-one scaffold binds to the hydrophobic pocket flanked 
by Ile10, Leu134, Lys33 and Val18. By visual inspection, a bifurcate 
hydrogen bond between backbone CO group of Gln131 and 
hydrazino group (2.54Å and 2.54Å) of the ligand was appeared. 
Another important hydrogen bond was formed between the 
terminal amino group of hydrazine moiety and Asp86 (2.9Å). In 
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addition some favorable hydrophobic contacts of p-nitrophenyl on 
the ligand with Ile10, Val18, Val64, Leu83, Leu134, Lys33, Phe80 
and Phe82 are appeared. The phenyl group at position 1 of the 
ligand was bordered with hydrophobic side chains of Thr14 and 
Lys129. These important hydrophobic and hydrogen bonds 
interactions are broadly agreed with attraction forces formed by 
CDK2 inhibitors. This could account for the highest potency of 
compound 5c. The results of this molecular docking study can support 
the postulation that our active compound may inhibit the growth of 
colon cell lines through inhibition of Cyclin Dependant kinase 2. 
 
   
Fig. 1: Docking of compound 5c (left panel) and erlotinib (right panel) into the active site of epidermal growth factor receptor. (Hydrogen 
bonds are showed in green dotted lines.) 
 
 
Fig. 2: Complex of ligand 5c with the active site of 
Cyclindependant Kinase2 (CDK2) 
 
Concerning the binding of compound 10b (fig. 3), it complexes with 
EGFR-TK in a fashion similar to compound 5c where the 
imidazotriazol-6-one scaffold binds to a hydrophobic pocket flanked 
by Ala719, Leu668, Leu694, Val702and Leu820 residues. We could 
observe that hydrogen bond interactions with Met-769 and water 
(HOH-10) were consisted. By visual inspection, it would expected 
that the aromatic moiety at position (3) is essential for activity 
where the sandwich-like aromatic stacking between phenyl and 
thioenyl moieties interact with side chains of Val702, Ala719, 
Lys721, Met742, Leu753, Leu764, ILeu765 and THr766, Thr830. 
This could account for the higher activity of 10b compared to 11a 
(4.3µg/ml and 4.7µg/ml respectively). 
These interactions illustrated the importance of imidazolidin-5-
one and imidazotriazol-6-one scaffolds along with hydrogen 
bonding features and hydrophobic moieties for binding and the 
subsequent inhibitory activity. The results of this molecular 
docking can support the postulation that our active target 
molecule may act on the same target enzyme where EGFR 
inhibitor acts confirming the molecular design of the reported 
class of antitumor agents. Binding of the selected compounds was 
expressed using Gold docking score which is taken as the negative 
of the sum of the component energy terms including the following 
four components:  
Protein-ligand hydrogen bond energy, protein-ligand Van der Waals 
energy, ligand internal Van der Waals energy and ligand to sional 
strain energy (internal torsional). (table 4, table 5). 
 
  
Fig. 3: Docking of compound 10b (left panel) and 11a (right panel) into the active site of epidermal growth factor receptor. Hydrogen 
bonds are showed in green dotted lines 
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Table 4: Gold docking score of the newly synthesized 
compounds compared with Erlotinib 










 10b 49.56 
11a 51.79 
 
Table 5: Gold docking score of the newly synthesized 
compounds compared with ATP 














Some of the newly synthesized compounds were evaluated for their 
antimicrobial activity using cup plate diffusion method [27-29]. 
Staphylococcus aureus (ATCC 6538), Staphylococcus epidermidis 
(ATCC 12228) and Micrococcus spp. (ATCC 10240) were be used as 
Gram-positive bacterial strains. Also, Pseudomonas aeruginosae 
(ATCC 9027), Klebsiella pneumoniae (ATCC 27736), Salmonella 
typhimurium (ATCC 14028) and Escherichia coli (ATCC 10536) were 
be used as Gram-negative bacterial strains. In addition, two fungi 
strains including Aspragillus niger (ATCC 16404) and Candida 
albicans (ATCC 10231) were be used in this evaluation. The results 
were reported as zone of inhibition compared to standard 
Cefotaxime and Sulphamethoxazole as antibacterial drugs and 
Nystatin as an antifungal drug. DMF was used as negative control. 
The results illustrated in table 2 and table 3 revealed that most of 
the newly synthesized compounds exhibit broad spectrum 
antimicrobial activity. Out of the compounds tested, Compounds 4h, 
6c and 12b showed only antifungal activity against both fungal 
strains. On the other hand, 10a and 11c are considered as the highest 
antifungal and anti Gram-positive strains respectively. Compounds 
4b, 4f, 6f and 12a showed antifungal as well as anti Gram-negative 
strains activities. Among these compounds, compound 6f showed 
the highest antifungal activity while compounds 6f and 12a possess 
the highest anti Gram-negative activity.  
CONCLUSION 
The present work led to the development of promising antitumor 
compounds containing substituted imidazolidin-5-one or 
imidazotriazol-6-one skeletons. Compounds 5c and 10b showed the 
highest potency at low µg/ml level against breast MCF-7 and colon 
HCT116 cell lines. It might be assumed that compounds bearing a 
hydrazine moiety as well as imidazotriazol-6-one scaffold are well 
binding site of EGFR and CDK2 receptor helps in understanding the 
antitumor selectivity over breast cancer MCF-7 and colon HCT116 
cell lines. Molecular docking studies further supported the highest 
potency of 5c and 10b and further help understanding the various 
interactions between the ligand and enzyme active sites in detail and 
thereby encourage to designing novel potent inhibitors. As evident 
from the experimental data and molecular docking studies, the 
pharmacophoric features essential for the antitumor activity of this 
series are aromatic ring separated by an average distance; H-
bonding acceptor donor and a hydrophobic moiety directly attached 
to the basic center. On the other hand, 6f and 10a are considered as 
the most antifungal compounds indicating the importance of thienyl 
moiety in the imidazole and imidazotriazol-6-one rings. Also, 
trimethoxy phenyl in the hydrazone compound 6f and the methyl 
substitution at position 3 in compound 10a may be responsible for 
anti fungal activity. Moreover, the most active compounds against 
Gram-negative bacterial strains are 6f, 7a, 12a and against Gram-
positive are 10a and 11c. From the above antitumor and 
antimicrobial activities, we can conclude that the thienyl moiety is 
essential for antimicrobial activity rather than antitumor activity. 
Also, the free hydrazino group which is a part of the most active 
antitumor compound 5c is not essential for antimicrobial activity. All 
these favorable features merits further investigations in our 
laboratories for further testing and derivatization in the hope of 
finding more selective and active molecules as antitumor and 
antimicrobial agents.  
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